Postoperative recurarization after sugammadex administration in two patients who received neoadjuvant chemotherapy: case reports and literature review
Background Preoperative neoadjuvant chemotherapy plays a critical role in multidisciplinary therapy for a variety of malignant tumours. Although oncologists consider myocardial injury to be the most concerning side effect of chemotherapy, unique chemotherapy-mediated skeletal muscular damage has received attention recently. Clinical features We report two unusual cases of postoperative delayed respiratory failure following administration of the recommended sugammadex dosage for patients undergoing lengthy operations with deep neuromuscular blockade (NMB) after neoadjuvant chemotherapy. Based on clinical outcomes, especially the comparison of muscle imaging results in patients at different treatment time points, we concluded that NMB recurrence had a possible correlation with neoadjuvant chemotherapy-induced muscular damage. Conclusion The early identification of neoadjuvant chemotherapeutic side effects on NMB could be instrumental for clinical safety, especially in cases of major surgery requiring deep NMB. Thus, the timing of NMB antagonism and the recommended dosage of sugammadex warrant special consideration in these patients. In addition to neuromuscular monitoring during the operation, a more extended and closer observation period in the postanesthesia care unit is warranted..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:70 |
|---|---|
| Enthalten in: |
Canadian journal of anesthesia - 70(2023), 9 vom: 05. Juli, Seite 1529-1538 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Hui-xian [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Case report |
|---|
| Anmerkungen: |
© Canadian Anesthesiologists' Society 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s12630-023-02527-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2145180397 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2145180397 | ||
| 003 | DE-627 | ||
| 005 | 20240118103145.0 | ||
| 007 | tu | ||
| 008 | 240118s2023 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12630-023-02527-x |2 doi | |
| 035 | |a (DE-627)OLC2145180397 | ||
| 035 | |a (DE-He213)s12630-023-02527-x-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Li, Hui-xian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Postoperative recurarization after sugammadex administration in two patients who received neoadjuvant chemotherapy: case reports and literature review |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © Canadian Anesthesiologists' Society 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Background Preoperative neoadjuvant chemotherapy plays a critical role in multidisciplinary therapy for a variety of malignant tumours. Although oncologists consider myocardial injury to be the most concerning side effect of chemotherapy, unique chemotherapy-mediated skeletal muscular damage has received attention recently. Clinical features We report two unusual cases of postoperative delayed respiratory failure following administration of the recommended sugammadex dosage for patients undergoing lengthy operations with deep neuromuscular blockade (NMB) after neoadjuvant chemotherapy. Based on clinical outcomes, especially the comparison of muscle imaging results in patients at different treatment time points, we concluded that NMB recurrence had a possible correlation with neoadjuvant chemotherapy-induced muscular damage. Conclusion The early identification of neoadjuvant chemotherapeutic side effects on NMB could be instrumental for clinical safety, especially in cases of major surgery requiring deep NMB. Thus, the timing of NMB antagonism and the recommended dosage of sugammadex warrant special consideration in these patients. In addition to neuromuscular monitoring during the operation, a more extended and closer observation period in the postanesthesia care unit is warranted. | ||
| 650 | 4 | |a case report | |
| 650 | 4 | |a deep neuromuscular block | |
| 650 | 4 | |a neoadjuvant chemotherapy | |
| 650 | 4 | |a recurarization | |
| 650 | 4 | |a sugammadex | |
| 700 | 1 | |a Zheng, Hui |4 aut | |
| 700 | 1 | |a Tang, Wei |4 aut | |
| 700 | 1 | |a Sun, Yong-kun |4 aut | |
| 700 | 1 | |a Zhang, Lin |4 aut | |
| 700 | 1 | |a Kong, Xiang-yi |4 aut | |
| 700 | 1 | |a Yan, Tao |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Canadian journal of anesthesia |d Springer International Publishing, 1987 |g 70(2023), 9 vom: 05. Juli, Seite 1529-1538 |w (DE-627)129282650 |w (DE-600)91002-8 |w (DE-576)01446876X |x 0832-610X |7 nnns |
| 773 | 1 | 8 | |g volume:70 |g year:2023 |g number:9 |g day:05 |g month:07 |g pages:1529-1538 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s12630-023-02527-x |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 951 | |a AR | ||
| 952 | |d 70 |j 2023 |e 9 |b 05 |c 07 |h 1529-1538 | ||